MedTrace Logo

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

NCT04154709 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-01-14

No results posted yet for this study

Summary

This study aims to evaluate the safety and feasibility of CTA101 in treating patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.

Conditions

Interventions

BIOLOGICAL

CTA101

Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.

Sponsors & Collaborators

  • Nanjing Bioheng Biotech Co., Ltd.

    collaborator INDUSTRY

  • Kai Lin Xu; Jun Nian Zheng

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-10
Primary Completion
2021-11-30
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04154709 on ClinicalTrials.gov